Dogwood Therapeutics (DWTX) Long-Term Debt Issuances (2020 - 2025)
Dogwood Therapeutics (DWTX) posted Long-Term Debt Issuances of $3.0 million for Q1 2025, up 2300.0% on a QoQ basis from $125000.0 in Q3 2020.
Analysis
Dogwood Therapeutics (DWTX) Long-Term Debt Issuances (2020 - 2025) Analysis & Trends
Dogwood Therapeutics has reported Long-Term Debt Issuances for 2 years, with the latest figure at $3.0 million in Q1 2025.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $3.0 million in Q1 2025; TTM through Dec 2025 was $3.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.0 million, down 80.42% from the prior year.
- Long-Term Debt Issuances was $3.0 million for Q1 2025 at Dogwood Therapeutics, up from $125000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $3.0 million in Q1 2025, with the low at $3.0 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.32 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Dogwood Therapeutics | 65.53 Mn | 65.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 3.00 Mn |
| Sep 30, 2020 | 125,000.00 |
| Jun 30, 2020 | 706,633.00 |
| Mar 31, 2020 | 1.16 Mn |